To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique
Introduction: Despite the growing body of evidence supporting the efficacy of subconjunctival bevacizumab injection, questions remain regarding its comparative effectiveness against conventional surgical techniques. Aims and Objectives: The aim of the study was to evaluate the efficacy of subconjunc...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of Clinical Ophthalmology and Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jcor.jcor_24_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction:
Despite the growing body of evidence supporting the efficacy of subconjunctival bevacizumab injection, questions remain regarding its comparative effectiveness against conventional surgical techniques.
Aims and Objectives:
The aim of the study was to evaluate the efficacy of subconjunctival bevacizumab injection before pterygium surgery with bare sclera technique in preventing postoperative reoccurrence.
Materials and Methods:
The present study was a comparative, randomized prospective study. Patients included were divided into two groups of 50 patients each. Patients in Group A received bevacizumab 2.5 mg/0.1 ml, and patients in Group B received subconjunctival balanced salt solution 0.1 ml. The primary outcome was recurrence of pterygium at 6 weeks and 6 months.
Results:
The total number of patients was 100. The mean age was 36.9 ± 8.67 years. The left eye was involved in more, i.e., 61 than the right eye 39. Majority of patients in Group A, i.e., 30 (60%) and in Group B 31 (62%) had Grade 2 pterygium, followed by Grade 3 pterygium in 17 (34%) in Group A and 15 (30%) in Group B. The recurrence rate at 6 weeks was 6% (3 patients) in Group A while it was 22% (11 patients) in Group B (P = 0.021). The recurrence rate at 6 months was 8% (4 patients) in Group A while it was 26% (13 patients) in Group B (P = 0.017).
Conclusion:
Subconjunctival injection of bevacizumab before surgery of pterygium is safe and effective in terms of recurrence and the complication rate for primary or recurrent pterygium treatment. |
|---|---|
| ISSN: | 2320-3897 2320-3900 |